Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics reports developments as a clinical-stage biotechnology company developing immunology therapies for autoimmune and chronic inflammatory diseases. Company news centers on rezpegaldesleukin, also known as REZPEG or NKTR-358, a regulatory T cell stimulator evaluated across disease areas including atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.
Recurring updates also cover Nektar's preclinical pipeline, including TNFR2 antibody and bispecific programs NKTR-0165 and NKTR-0166, and the modified hematopoietic colony stimulating factor protein NKTR-422. Financial results, public equity offerings, shelf-registration activity, employee inducement grants, and other capital and governance actions are regular news themes for NKTR.
Nektar Therapeutics (Nasdaq: NKTR) unveiled preclinical data on NKTR-0165, a TNFR2 agonist antibody aimed at treating inflammatory diseases, at the EULAR 2024 Congress. NKTR-0165 is designed to selectively stimulate TNFR2 receptor activity, which is important for inflammation control and is associated with various autoimmune diseases like ulcerative colitis and vitiligo. Preclinical studies revealed that NKTR-0165 enhances Treg cell function, a key component in immune response regulation, without affecting TNFR1 signaling. IND-enabling studies are ongoing, with human trials expected in the first half of 2025.
Nektar Therapeutics (Nasdaq: NKTR) management will present at two upcoming investor conferences: the Jefferies Healthcare Conference in New York City on June 6, 2024, at 3:30 p.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 10, 2024, at 2:00 p.m. ET.
The presentations will be webcast live and accessible via the Investor Events section on the Nektar website. Recordings of the webcasts will be available until July 6, 2024, and July 10, 2024, respectively.
Nektar Therapeutics reported their financial results for the first quarter of 2024, showing revenue of $21.6 million and a net loss of $36.8 million. The company's cash and investments were $326.0 million as of March 31, 2024, supporting operations until the third quarter of 2026. Progress was noted in their immunology and inflammation pipeline, with expectations for topline data from ongoing trials in 2025. Nektar also entered into a private placement financing agreement generating $30 million in gross proceeds.
Nektar Therapeutics (NKTR) will announce its financial results for the first quarter of 2024 on May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and CEO, will host a conference call to review the results. The press release and webcast link will be available on the Nektar website. Conference call replay will be accessible until June 9, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.